December 21, 2022
The study tested the effectiveness of removing small tumors from the kidney using the company’s device, which destroys tumors by freezing them in liquid nitrogen. The company took advantage of the momentum in the stock market to raise $14.5 million
The medical device company IceCure from Caesarea presented interim results of a study that tested the effectiveness of using the ProSense device it developed to treat patients who were found to have a small cancerous tumor in their kidneys and for whom the only surgical alternative is to surgically remove a kidney. The ProSense device is a minimally invasive device that injects, through thin tubes, liquid nitrogen, which forms an ice ball in a targeted manner at the heart of the tumor and destroys it.
According to the results of the study, which was presented at the conference of the Association of Urologists in Eilat last week by Dr. Nazir Zaid from Beit Zion Medical Center, 89.5% of the group of patients who developed a tumor of 3 cm or less on their kidney – and which was removed using the ProSense) – did not experience Tumor recurrence at follow-up 22.2 months after removal. The average patient treatment took about 25 minutes, under partial anesthesia, and the hospitalization lasted only about two days. According to the American Cancer Society, there has been an increase in the last decade in the number of people diagnosed with kidney cancer. In 2022, about 79,000 patients will be diagnosed, and according to statistics, about 14,000 of them will die. The findings presented by Eyesure in the study are better than the success rate of surgical operation, what’s more, the procedure is non-invasive, cheaper and does not involve excision.
In recent years, iSure has focused, at the business and clinical level, on the designation of the device for the treatment of early-stage breast cancer, since its assessment of its device has the greatest relative advantages in this type of cancer. However, the ProSense is actually used to treat other types of cancer, including bone, liver and kidney. The ProSense is approved by the FDA for use in kidney cancer, and it is estimated that soon the indication will also be extended to breast cancer under certain criteria, after the company recently presented interim findings from a comprehensive study it conducted in the United States. In the field of kidney cancer, there are alternative minimally invasive treatments, either by destroying the tumor using heat energy or freezing using argon gas, but the clinical data on them is scarce. Following the announcement, the company’s stock jumped by hundreds of contracts yesterday. The company took advantage of this and during Bezeq, today (Wednesday) raised about 14.5 million dollars through the allocation of shares at a price of 1.65 dollars per share.
Published in the categories: news, medical devices
Posted in tags: Eyecure, kidney cancer
